Abstract: The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the detection of HBV in biological samples. In particular, oligonucleotide sequences are provided for the sensitive qualitative or quantitative detection of all eight HBV genotypes. The invention also provides oligonucleotide primer sets and primer/probe sets in the form of kits for the diagnosis of HBV infection.

Abstract: The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2D6 polymorphisms, in particular CYP2D6 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2D6.

Abstract: The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2C9 polymorphisms, in particular CYP2C9 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2C9.

Abstract: Provided is a kinetic PCR (“kPCR”) assay for determining gene copy number of a target gene located on chromosome 17. The kPCR assay uses the MMP-28 gene located at the 17q11.2-17q12 loci as a control and thus, is capable of detecting gene copy number of any gene on chromosome 17 in both singleplex and multiplex format without the need for a standard curve. The kPCR assay is useful for determining the gene copy number of the HER2/neu gene located at loci 17q12-17q21.32, which is a requirement for determining if a breast cancer patient is a candidate for anti-HER2/neu gene therapy.

Abstract: Methods are provided for highly sensitive and rapid in situ detection of a nucleic acid analyte of a known sequence. The method employs oligonucleotide probes in a series of optimized steps to amplify a signal and decrease background. Sensitivity is enhanced such that the method can detect as few as 1–2 copies of nucleic acid analyte per sample, the sample containing a cell, tissue or similar biological material. Methods of detecting and identifying the position of the nucleic acid analyte in a cell are also provided.

Abstract: Methods are provided for highly sensitive and rapid in situ detection of a nucleic acid analyte of a known sequence. The method employs oligonucleotide probes in a series of optimized steps to amplify a signal and decrease background. Sensitivity is enhanced such that the method can detect as few as 1-2 copies of nucleic acid analyte per sample, the sample containing a cell, tissue or similar biological material. Methods of detecting and identifying the position of the nucleic acid analyte in a cell are also provided.

Abstract: Novel DNA probe sequences for detection of CMV in a sample in a solution phase sandwich hybridization assay are described. Amplified nucleic acid hybridization assays using the probes are exemplified.